The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Open accessAbstract
BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mardis et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“In an AML case with an IDH1 mutation that was sequenced in its entirety (Mardis et al., 2009), there were a relatively small total number of somatic, non-synonymous mutations.”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [170]
In the citing paper
“the lack of evidence that 2HG was acting as a mutagen (Mardis et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [129]
In the citing paper
“Treatment of AML with targeted therapies is particularly promising due to the fact that AMLs have far fewer mutations than most other adult cancers, with an average of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas Research Network, 2013).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Mardis et al, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Methods of Detection of Measurable Residual Disease in AML
Zhou, Y., & Wood, B. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0419-5 · Cited by 41
Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
Caiado, F., Maia-Silva, D., Jardim, C., Schmolka, N., Carvalho, T., Reforço, C., Faria, R., Kolundžija, B., Simões, A. E. S., Baubec, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12983-z · Cited by 41
Genomic sequencing in clinical trials
Mestan, K. K. L., Ilkhanoff, L., Mouli, S., & Lin, S. M. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-222 · Cited by 41
Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia
Curran, E. K., Corrales, L. P., & Kline, J. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00083 · Cited by 41
Bisht, P., Kumar, V. U., Pandey, R., Ravichandiran, V., & Kumar, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.939570 · Cited by 40
Hoffmann, J., & Cazaux, C. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.001 · Cited by 40
Expression profiling of leukemia patients: Key lessons and future directions
Shivarov, V. S., & Bullinger, L. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.04.006 · Cited by 40
The molecular pathogenesis of myelodysplastic syndromes
Davids, M. S., & Steensma, D. P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.4.12612 · Cited by 40
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia
Bruserud, Ø., Nepstad, I., Hauge, M., Hatfield, K. J., & Reikvam, H. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.971005 · Cited by 40
A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Shanmugam, R., Gade, P., Wilson-Weekes, A., Sayar, H., Suvannasankha, A., Goswami, C. P., Li, L., Gupta, S. K., Cardoso, A. A., Baghdadi, T. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3022 · Cited by 40
Human genome at ten: The sequence explosion
(2010) · Nature · doi:10.1038/464670a · Cited by 40
Hollink, I. H. I. M., Feng, Q., Oorschot, A. A. D.-V., Arentsen-Peters, S. T. C. J. M., Verboon, L., Zhang, P., de Haas, V., Reinhardt, D., Creutzig, U., Trka, J., et al. (2011) · Leukemia · doi:10.1038/leu.2011.210 · Cited by 39
Zhang, Y., Yan, X., Sashida, G., Zhao, X., Rao, Y., Goyama, S., Whitman, S. P., Zorko, N. A., Bernot, K. M., Conway, R. M., et al. (2012) · Blood · doi:10.1182/blood-2012-02-412379 · Cited by 39
NGS catalog: A database of next generation sequencing studies in humans
Xia, J., Wang, Q., Jia, P., Wang, B., Pao, W. J., & Zhao, Z. (2012) · Human Mutation · doi:10.1002/humu.22096 · Cited by 39
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Ragon, B. K., & Dinardo, C. D. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0418-6 · Cited by 39
Longuespée, R., Wefers, A. K., Vita, E. D., Miller, A. K., Reuß, D., Wick, W., Herold‐Mende, C. C., Kriegsmann, M., Schirmacher, P., von Deimling, A., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0523-3 · Cited by 39
Alteraciones moleculares en leucemia mieloide aguda y sus implicaciones clínicas y terapéuticas
Infante, M. S., Piris, M. A., & Hernández‐Rivas, J. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.05.002 · Cited by 39
Targeting Energy Metabolism in Cancer Treatment
Kubik, J., Humeniuk, E., Adamczuk, G., Madej, B., & Korga-Plewko, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105572 · Cited by 39
Wright, J. (2013) · Nature · doi:10.1038/498s10a · Cited by 39
Molecular prognostic factors in cytogenetically normal acute myeloid leukemia
Walker, A., & Marcucci, G. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.45 · Cited by 39
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System
Nieto‐Sampedro, M., Valle‐Argos, B., Gómez‐Nicola, D., Fernández‐Mayoralas, A., & Nieto‐Díaz, M. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7685 · Cited by 39
IDH1, lipid metabolism and cancer: Shedding new light on old ideas
Bogdanovic, E. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.04.014 · Cited by 39
Singh, R. R., Luthra, R., Routbort, M. J., Patel, K. P., & Medeiros, L. J. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2015.1120401 · Cited by 39
Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis
Teng, X., Emmett, M. J., Lazar, M. A., Goldberg, E., & Rabinowitz, J. D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00290 · Cited by 39
Ma, S., Sun, R., Jiang, B., Gao, J., Deng, W., Liu, P., He, R., Cui, J., Ji, M., Yi, W., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00492-16 · Cited by 39
Xie, J., Sheng, M., Rong, S., Zhou, D., Wang, C., Wu, W., Huang, J., Sun, Y., Wang, Y., Chen, P., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02055-z · Cited by 39
Oizel, K., Gratas, C., Nadaradjane, A., Oliver, L., Vallette, F. M., & Pecqueur, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.13 · Cited by 38
New Fusion Transcripts Identified in Normal Karyotype Acute Myeloid Leukemia
Wen, H., Li, Y., Malek, S. N., Kim, Y. C., Xu, J., Chen, P., Xiao, F., Huang, X., Zhou, X., Xuan, Z., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051203 · Cited by 38
Splicing factor mutations in myelodysplasia
Ogawa, S. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1182-y · Cited by 38
Power Cut: Inhibiting Mitochondrial Translation to Target Leukemia
Järås, M., & Ebert, B. L. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.028 · Cited by 38
Itonaga, H., Imanishi, D., Wong, Y.-F., Sato, S., Ando, K., Sawayama, Y., Sasaki, D., Tsuruda, K., Hasegawa, H., Imaizumi, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2014.15 · Cited by 38
Falini, B., Sportoletti, P., Brunetti, L., & Martelli, M. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13409 · Cited by 38
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
Ohba, S., & Hirose, Y. (2016) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0322 · Cited by 38
Pikman, Y., Tasian, S. K., Sulis, M. L., Stevenson, K. E., Blonquist, T. M., Winger, B. A., Cooper, T. M., Pauly, M. G., Maloney, K. W., Burke, M. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0564 · Cited by 38
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Sule, A. D., Doorn, J. V., Sundaram, R. K., Ganesa, S., Vasquez, J. C., & Bindra, R. S. (2021) · NAR Cancer · doi:10.1093/narcan/zcab018 · Cited by 38
Multistep tumorigenesis in peripheral T cell lymphoma
Sakata‐Yanagimoto, M. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1738-8 · Cited by 38
The changing paradigm of prognostic factors in acute myeloid leukaemia
Grimwade, D. J. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.10.004 · Cited by 37
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Jin, G., Pirozzi, C. J., Chen, L. H., Lopez, G. Y., Duncan, C. G., Feng, J., Spasojević, I., Bigner, D. D., He, Y., & Yan, H. (2012) · Oncotarget · doi:10.18632/oncotarget.577 · Cited by 37
Targeting the IDH2 Pathway in Acute Myeloid Leukemia
Amaya, M. L., & Pollyea, D. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0536 · Cited by 37
Wei, S., Wang, J., Oyinlade, O., Ma, D., Wang, S., Kratz, L. E., Lal, B., Xu, Q., Liu, S., Shah, S. R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0334-9 · Cited by 37
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Patel, J. P., & Levine, R. L. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.28.3797923 · Cited by 37
Insights into cell ontogeny, age, and acute myeloid leukemia
Chaudhury, S., Morison, J., Gibson, B. E. S., & Keeshan, K. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.008 · Cited by 37
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
Al‐Kali, A., Quintás‐Cardama, A., Luthra, R., Bueso-Ramos, C., Pierce, S. A., Kadia, T. M., Borthakur, G. M., Estrov, Z. E., Jabbour, E. J., Faderl, S. H., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23410 · Cited by 37
Mitochondrial energy metabolism and apoptosis regulation in glioblastoma
Nagy, Á., Éder, K., Selak, M. A., & Kálmán, B. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.062 · Cited by 37
Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate
Rakheja, D., Boriack, R. L., Mitui, M., Khokhar, S., Holt, S. A., & Kapur, P. (2010) · Tumor Biology · doi:10.1007/s13277-010-0125-6 · Cited by 37
Damm, F., Bunke, T., Thol, F. R., Markus, B., Wagner, K., Göhring, G., Schlegelberger, B., Heil, G., Reuter, C. W., Püellmann, K., et al. (2011) · Leukemia · doi:10.1038/leu.2011.200 · Cited by 37
Foley, S. B., Hildenbrand, Z. L., Soyombo, A. A., Magee, J. A., Wu, Y., Oravecz-Wilson, K. I., & Ross, T. S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.037 · Cited by 37
Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia
Celton, M., Forest, A., Gosse, G., Lemieux, S., Hébert, J., Sauvageau, G., & Wilhelm, B. T. (2014) · Leukemia · doi:10.1038/leu.2014.67 · Cited by 37
Tuna, M., & Amos, C. I. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.004 · Cited by 37
Applications of Next-Generation Sequencing in Systemic Autoimmune Diseases
Ma, Y., Shi, N., Li, M., Chen, F., & Niu, H. (2015) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.09.004 · Cited by 37
Pathogenic Mechanisms in Acute Myeloid Leukemia
Chakraborty, S., & Park, C. Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01021-8 · Cited by 36
Platt, M. Y., Fathi, A. T., Borger, D. R., Brunner, A. M., Hasserjian, R. P., Balaj, L., Lum, A. M., Yip, S. S. F., Dias-Santagata, D. C., Zheng, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.004 · Cited by 36
Self-citationChokkalingam, A. P., Metayer, C., Scélo, G., Chang, J. S.-M., Urayama, K. Y., Aldrich, M. C., Guha, N., Hansen, H. M., Dahl, G. V. H., Barcellos, L. F., et al. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9947-4 · Cited by 36
Integrated analysis of recurrent properties of cancer genes to identify novel drivers
D’Antonio, M., & Ciccarelli, F. D. (2013) · Genome biology · doi:10.1186/gb-2013-14-5-r52 · Cited by 36
Kim, H., Kim, S., Lee, H. H., & Heo, H. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.5.620 · Cited by 36
Novel therapies for AML: a round-up for clinicians
Swaminathan, M., & Wang, E. S. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1850255 · Cited by 36
Molina, L. M., Zhu, J., Trépo, E., Bayard, Q., Amaddeo, G., Bail, B. L., Chiche, L., Bioulac‐Sage, P., Balabaud, C. P., Possenti, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.018 · Cited by 36
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Liu, Y., Xu, W., Li, M., Yang, Y., Sun, D., Chen, L., Li, H., & Chen, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.019 · Cited by 37
Chiu, S., Liu, H.-H., Chen, C., Chen, P.-R., Liu, M.-C., Lin, S., & Chang, K. (2015) · Cell Transplantation · doi:10.3727/096368915x686850 · Cited by 36
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia
Caramazza, D., Lasho, T. L., Finke, C. M., Gangat, N., Dingli, D., Knudson, R. A., Siragusa, S. M., Hanson, C. A., Pardanani, A. D., Ketterling, R. P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.213 · Cited by 36
The Genomic Architecture of Sporadic Heart Failure
Dorn, G. W. (2011) · Circulation Research · doi:10.1161/circresaha.110.229260 · Cited by 36
Venneker, S., Kruisselbrink, A. B., Bruijn, I. H. B., de Jong, Y., van Wijnen, A. J., Danen, E. H. J., & Bovée, J. V. M. G. (2019) · Cancers · doi:10.3390/cancers11121918 · Cited by 36
SAVI: a statistical algorithm for variant frequency identification
Trifonov, V., Pasqualucci, L., Tiacci, E., Falini, B., & Rabadán, R. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-s2-s2 · Cited by 36
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
THE REFERENCE HUMAN GENOME DEMONSTRATES HIGH RISK OF TYPE 1 DIABETES AND OTHER DISORDERS
Chen, R., & Butte, A. J. (2010) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814335058_0025 · Cited by 35
Molecular cytogenetics: recent developments and applications in cancer
Das, K., & Tan, P. B. O. (2013) · Clinical Genetics · doi:10.1111/cge.12229 · Cited by 35
A new branch on the tree: Next-generation sequencing in the study of cancer evolution
Brosnan‐Cashman, J. A., & Iacobuzio–Donahue, C. A. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2011.12.008 · Cited by 35
Ma, Q. C., Ennis, C. A., & Aparicio, S. A. J. R. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.01.008 · Cited by 35
Activity-based proteomic and metabolomic approaches for understanding metabolism
Hunerdosse, D. M., & Nomura, D. K. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.02.001 · Cited by 35
Tian, X., Pelton, A. K., Shahsafaei, A., & Dorfman, D. M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.114 · Cited by 35
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective
Ma, T., Zou, F., Pusch, S., Xu, Y., von Deimling, A., & Zha, X. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00159 · Cited by 35
Grassi, S., Guerrini, F., Ciabatti, E., Puccetti, R., Salehzadeh, S., Metelli, M. R., Vita, A. D., Domenichini, C., Caracciolo, F., Orciuolo, E., et al. (2020) · Cancers · doi:10.3390/cancers12071738 · Cited by 35
Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
Zhao, Y., Feng, F., Guo, Q., Wang, Y., & Zhao, R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i34.5074 · Cited by 35
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away
Nagai, Y., & Ambinder, A. J. (2023) · Cancers · doi:10.3390/cancers15143535 · Cited by 35
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
Wang, P., Lv, C., & Zhu, G. (2015) · Scientific Reports · doi:10.1038/srep09150 · Cited by 35
Brunner, A. M., Neuberg, D. S., Wander, S. A., Sadrzadeh, H., Ballen, K. K., Amrein, P. C., Attar, E. C., Hobbs, G. S., Chen, Y., Perry, A. M., et al. (2018) · Cancer · doi:10.1002/cncr.31729 · Cited by 35
Self-citationWarburg and Krebs and related effects in cancer
Unterlass, J. E., & Curtin, N. J. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.4 · Cited by 35
The expression and significance of IDH1 and p53 in osteosarcoma
Hu, X., Yu, A., Qi, B., Fu, T., Wu, G., Zhou, M., Luo, J., & Xu, J.-H. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-43 · Cited by 35
Somatic mutations in cancer development
Luzzatto, L. (2011) · Environmental Health · doi:10.1186/1476-069x-10-s1-s12 · Cited by 35
Integration of hypoxic HIF-α signaling in blood cancers
Schito, L., Rey, S., & Konopleva, M. Y. (2017) · Oncogene · doi:10.1038/onc.2017.119 · Cited by 34
Chen, D., Xia, S., Wang, M., Lin, R., Li, Y., Mao, H. Z., Aguiar, M., Famulare, C. A., Shih, A. H., Brennan, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1040 · Cited by 34
Olutasidenib: from bench to bedside
Venugopal, S., & Watts, J. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009854 · Cited by 34
Abbas, S., Sanders, M. A., Zeilemaker, A., Geertsma-Kleinekoort, W. M. C., Koenders, J. E., Kavelaars, F. G., Abbas, Z. G., Mahamoud, S., Chu, I. W. T., Hoogenboezem, R. M., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.095604 · Cited by 34
CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia
Dang, H., Chen, Y., Kamel‐Reid, S., Brandwein, J. M., & Chang, H. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.03.007 · Cited by 34
Singh, H., Lane, A. A., Correll, M., Przychodzen, B. P., Sykes, D. B., Stone, R. M., Ballen, K. K., Amrein, P. C., Maciejewski, J. P., & Attar, E. C. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.16 · Cited by 34
Whole-exome sequencing reveals recurrent somatic mutation networks in cancer
Liu, X., Wang, J., & Chen, L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.002 · Cited by 34
Gebhard, C., Glatz, D., Schwarzfischer, L., Wimmer, J., Stasik, S., Nuetzel, M., Heudobler, D., Andreesen, R., Ehninger, G., Thiede, C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0165-2 · Cited by 34
Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia
Sekeres, M. A., & Steensma, D. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2962 · Cited by 34
Jiang, B., Zhang, J., Xia, J., Zhao, W., Wu, Y., Shi, M., Luo, L., Zhou, H., Chen, A., Ma, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.053 · Cited by 33
NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival
Tewarie, N. M. S. B., Burgers, I. A. V., Dawood, Y., den Boon, H. C., den Brok, M. G. H. E., Klunder, J. H., Koopmans, K. B., Rademaker, E., van den Broek, H. B., van den Bersselaar, S. M., et al. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.02.022 · Cited by 33
Epigenetic alterations and microRNAs
Vasilatou, D., Papageorgiou, S. G., Dimitriadis, G., & Pappa, V. (2013) · Epigenetics · doi:10.4161/epi.24897 · Cited by 33
Molecular markers in acute myeloid leukaemia
Kühnl, A., & Grimwade, D. J. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1123-9 · Cited by 33
Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines
Li, L., Goedegebuure, P. S., Mardis, E. R., Ellis, M. J., Zhang, X., Herndon, J. M., Fleming, T. P., Carreno, B. M., Hansen, T. H., & Gillanders, W. E. (2011) · Cancers · doi:10.3390/cancers3044191 · Cited by 33
Self-citationMolecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
Eason, K., & Sadanandam, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0141 · Cited by 33
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33
Upadhyay, V. A., Brunner, A. M., & Fathi, A. T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.003 · Cited by 33
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, C. M., Llop, M., Sargas, C., Pedrola, L., Panadero, J., Hervás, D., Cervera, J., Such, E., Ibáñez, M., Ayala, R. M., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.09.009 · Cited by 33
Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening
Wang, Y., Tang, S., Lai, H., Jin, R., Xu, L., Li, N., Tang, Y., Guo, H., Yao, X., & Leung, E. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.579768 · Cited by 33
Self-citation
Metadata
- Authors
- Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J., Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E., McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J., Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J., Graubert, T. A., DiPersio, J. F., Wilson, R. K., & Ley, T. J.
- Affiliations
- Washington University in St. Louis (US)
- Alvin J. Siteman Cancer Center (US)
- ORCID
- Mardis, Elaine R.
- Ding, Li
- Larson, David E.
- McLellan, Michael D.
- Chen, Ken
- Koboldt, Daniel C.
- Fulton, Robert S.
- McGrath, Sean D.
- Magrini, Vincent J.
- Vickery, Tammi L.
- Wylie, Todd
- Walker, Jason
- McMichael, Joshua F.
- Pohl, Craig S.
- Tang, Yuzhu
- Ries, Rhonda E.
- Payton, Jacqueline E.
- Tomasson, Michael H.
- Watson, Mark A.
- Heath, Sharon
- Link, Daniel C.
- Walter, Matthew J.
- Graubert, Timothy A.
- DiPersio, John F.
- Wilson, Richard K.
- Ley, Timothy J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1058-1066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3201812
- OpenAlex
- W2134061682
- Cited by
- 2,219
- References
- 31
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 57 · 2023: 76 · 2022: 81 · 2021: 107 · 2020: 104 · 2019: 115 · 2018: 120 · 2017: 126 · 2016: 136 · 2015: 154 · 2014: 163 · 2013: 197 · 2012: 251
- FWCI
- 154.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (U54HG003079)
- National Cancer Institute (P01CA101937)
- National Center for Research Resources (UL1RR024992)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, somatic mutations, IDH1 mutation, NPM1 mutation, NRAS mutation, cytogenetically normal AML, tumor genome sequencing
- MeSH terms
- Nucleophosmin, Adult, DNA Mutational Analysis, Female, Gene Frequency, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Genome, Human, Point Mutation, Sequence Analysis, DNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
